TRAVASOL INJ WITHOUT ELECTROLYTES 8.5% 1.76 G / 100 ML
L-ALANINE : 1.76 G / 100 ML PHENYLALANINE : 526 MG / 100 ML TYROSINE : 34 MG / 100 ML VALINE : 390 MG / 100 ML PROLINE : 356 MG / 100 ML L-LYSINE HYDROCHLORIDE : 492 MG / 100 ML HISTIDINE : 372 MG / 100 ML THREONINE : 356 MG / 100 ML ARGININE : 880 MG / 100 ML LEUCINE : 526 MG / 100 ML TRYPTOPHAN : 152 MG / 100 ML ISOLEUCINE : 406 MG / 100 ML GLYCINE : 1.76 G / 100 ML DL-METHIONINE : 492 MG / 100 ML · DIN 00388750 · BAXTER CORPORATION
Health Canada status: CANCELLED POST MARKET
What is TRAVASOL INJ WITHOUT ELECTROLYTES 8.5%?
TRAVASOL INJ WITHOUT ELECTROLYTES 8.5% 1.76 G / 100 ML contains L-ALANINE : 1.76 G / 100 ML PHENYLALANINE : 526 MG / 100 ML TYROSINE : 34 MG / 100 ML VALINE : 390 MG / 100 ML PROLINE : 356 MG / 100 ML L-LYSINE HYDROCHLORIDE : 492 MG / 100 ML HISTIDINE : 372 MG / 100 ML THREONINE : 356 MG / 100 ML ARGININE : 880 MG / 100 ML LEUCINE : 526 MG / 100 ML TRYPTOPHAN : 152 MG / 100 ML ISOLEUCINE : 406 MG / 100 ML GLYCINE : 1.76 G / 100 ML DL-METHIONINE : 492 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00388750, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 26-Mar-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00388750 |
|---|---|
| Brand name | TRAVASOL INJ WITHOUT ELECTROLYTES 8.5% |
| Generic / active ingredient | L-ALANINE : 1.76 G / 100 ML PHENYLALANINE : 526 MG / 100 ML TYROSINE : 34 MG / 100 ML VALINE : 390 MG / 100 ML PROLINE : 356 MG / 100 ML L-LYSINE HYDROCHLORIDE : 492 MG / 100 ML HISTIDINE : 372 MG / 100 ML THREONINE : 356 MG / 100 ML ARGININE : 880 MG / 100 ML LEUCINE : 526 MG / 100 ML TRYPTOPHAN : 152 MG / 100 ML ISOLEUCINE : 406 MG / 100 ML GLYCINE : 1.76 G / 100 ML DL-METHIONINE : 492 MG / 100 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 1.76 G / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA01 AMINO ACIDS |
| AHFS class | 40:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 26-Mar-2008 |
| Original market date | 1978-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05BA01 AMINO ACIDS. 4 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 20% PROSOL | 1.18 G / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02141450 |
| ESSEPNA | 1.1 G / 100 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02510324 |
| PRIMENE 10% | 189 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | DIN 02236875 |
| TRAVASOL | 600 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00872296 |
| 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX | 76 MG / 100 ML | SOLUTION | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02013908 |
| 8.5% FREAMINE III | 770 MG / 100 ML | LIQUID | B. BRAUN MEDICAL INC | CANCELLED POST MARKET | DIN 02158647 |
| AMINOSYN | 440 MG / 100 ML | SOLUTION | ICU MEDICAL CANADA INC | CANCELLED POST MARKET | DIN 00454907 |
| AMINOSYN 5% | 220 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00404160 |
| AMINOSYN 7% | 690 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00523232 |
| AMINOSYN 8.5% | 624 MG / 100 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00613320 |
Who else supplies AMINO ACIDS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMINO ACIDS appears in 215 registered pack listings across 5 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.